Avoid common mistakes on your manuscript.
Dear Editor,
With great interest, we read the comprehensive systematic review by Shanika et al. [1] which highlights the high consumption of proton pump inhibitors (PPI) by about a quarter of the adults (23,4%) worldwide. In their conclusions, the authors stress the need for a rational use, better monitoring, and deprescribing where indications are lacking. We fully agree with these conclusions, but we would like to add the following aspect: the lack of PPI despite indication.
For Germany, high treatment prevalence has been reported [2], especially in patients with polypharmacy and multimorbidity. For the latter, Lappe et al. reported a treatment prevalence with PPI of 52% and a high mean amount of 442 defined daily doses (DDD) in 2019, indicating continuous treatment or high daily doses [3].
Despite high treatment prevalence with PPI, undersupply can be observed, especially when patients use, e.g., simultaneously NSAID and anticoagulants or glucocorticoids. The risk for gastrointestinal bleeding is increased compared to monotherapy with only one drug group [4]. To minimize the risk for gastric ulcer and stomach bleeding during treatment with these drugs, the prophylactic co-prescribing of PPI or other antiulcer drugs is recommended [5].
In order to investigate the extent of undersupply, we analyzed the data of one of the largest health insurance funds (BARMER) in Germany. The data was accessed via the scientific data warehouse. We focused on insured persons > 17 years of age without a diagnosis of malignant neoplasm (ICD-10 code C00-C97) and a simultaneous prescription of NSAID with (i) anticoagulants or antithrombotic agents (n = 82,756) and (ii) glucocorticoids (n = 41,319) over a period of at least 28 days in 2021. Drugs were classified according to the anatomical therapeutic chemical (ATC) classification.
According to our data, 40.0% of those with a simultaneous treatment of NSAID with anticoagulants/antithrombotic agents had no co-prescribing of a PPI, and only 0.1% received other drugs for acid-related disorders (H2-receptor antagonists, misoprostol). A comparable amount of 39.2% did not receive an indicated PPI while using NSAID and glucocorticoids for a longer period of time. Women seem to be more likely to receive a PPI [6]. Age has a stronger influence on the co-prescribing of PPI in patients with glucocorticoids compared to the other combination of drugs (Fig. 1).
In addition to the examples mentioned, there are further constellations where indicated PPI prescribing should be checked [5]. The strength of the study lies in the database covering about 12% of all statutory health-insured persons in Germany (9 million persons). Limitations are the lack of information on over-the-counter drugs and individual reasons for the use or nonuse of a drug.
The high treatment prevalence of PPI and long application time underline the need for a regular medication review as expressed by Shanika et al. [1]. International guidelines for the management of multimedication [7, 8] offer various instruments for medication assessment such as the Medication Appropriateness Index (MAI) [9]. While the risk of drugs and overuse in patients are frequently addressed, the possible underuse, i.e., a lack of a drug despite given indication, is less aware [10]. The German evidence-based guideline on multimedication [8] included underuse into the MAI as a key question when reviewing medication. As we could demonstrate for PPI, there may also be an undersupply of a commonly used medicine.
Data availability
Restrictions apply to the availability of these data. Data can be made available upon reasonable request and with permission of BARMER.
References
Shanika LGT, Reynolds A, Pattison S, Braund R (2023) Proton pump inhibitor use: systematic review of global trends and practices. Eur J Clin Pharmacol 79(9):1159–1172. https://doi.org/10.1007/s00228-023-03534-z
Rückert-Eheberg I-M, Nolde M, Ahn N, Tauscher M, Gerlach R, Güntner F, Günter A, Meisinger C, Linseisen J, Amann U et al (2022) Who gets prescriptions for proton pump inhibitors and why? A drug-utilization study with claims data in Bavaria, Germany, 2010–2018. Eur J Clin Pharmacol 78(4):657–667. https://doi.org/10.1007/s00228-021-03257-z
Lappe V, Dinh TS, Harder S, Brueckle M-S, Fessler J, Marschall U, Muth C, Schubert I, and on behalf of the EVITA Study Group (2022) Multimedication guidelines: assessment of the size of the target group for medication review and description of the frequency of their potential drug safety problems with routine data. Pharmacoepidemiology 1(1):12–25. https://doi.org/10.3390/pharma1010002
Masclee GM, Valkhoff VE, Coloma PM, de Ridder M, Romio S, Schuemie MJ, Herings R, Gini R, Mazzaglia G, Picelli G et al (2014) Risk of upper gastrointestinal bleeding from different drug combinations. Gastroenterology 147(4):784–792.e789; quiz e713–784. https://doi.org/10.1053/j.gastro.2014.06.007
Grandt D, Gamstätter T (2021) S2k-Leitlinie Arzneimitteltherapie bei Multimorbidität – living guideline. https://register.awmf.org/assets/guidelines/100-001l_S2k_Arzneimitteltherapie-bei-Multimorbiditaet_2023-02.pdf. Accessed 27 Aug 2023
Grandt D, Lappe V, Schubert I (2023) Arzneimittelreport 2023: Medikamentöse Schmerztherapie nicht-onkologischer ambulanter Patientinnen und Patienten Berlin, BARMER (in print)
NICE Medicines and Prescribing Centre (UK) (2015) Medicines optimisation: the safe and effective use of medicines to enable the best possible outcomes. Manchester: National Institute for Health and Care Excellence (NICE). https://www.nice.org.uk/guidance/ng5/evidence/full-guideline-pdf-6775454. Accessed 30 Aug 2023
Schubert I, Fessler J, Harder S, Dinh TS, Brueckle M-S, Muth C and on behalf of the EVITA Study Group (2022) Multimedication in family doctor practices: the German evidence-based guidelines on multimedication. Pharmacoepidemiology 1(1):35–48. https://doi.org/10.3390/pharma1010005
Hanlon JT, Schmader KE (2022) The medication appropriateness index: a clinimetric measure. Psychother Psychosom 91(2):78–83. https://doi.org/10.1159/000521699
Kuijpers MA, van Marum RJ, Egberts AC, Jansen PA (2008) Relationship between polypharmacy and underprescribing. Br J Clin Pharmacol 65(1):130–133. https://doi.org/10.1111/j.1365-2125.2007.02961.x
Acknowledgements
Open Access funding was enabled by Project DEAL.
Funding
Open Access funding enabled and organized by Projekt DEAL. IS and VL received funding from the BARMER. UM is employed by the BARMER; DG received funding from the BARMER. The analysis was funded by the BARMER.
Author information
Authors and Affiliations
Contributions
IS, VL and DG designed the study, VL analyzed the data; IS wrote the manuscript, VL, UM and DG supervised the manuscript. All authors have read and agreed to the published version.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no competing interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Schubert, I., Lappe, V., Marschall, U. et al. Missing PPI prescriptions while overprescribing?. Eur J Clin Pharmacol 79, 1579–1581 (2023). https://doi.org/10.1007/s00228-023-03564-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-023-03564-7